WellGen Obtains License to Obesity Genes

WellGen, a biotechnology company using nutrigenomics to develop proprietary wellness products, has signed a research contract and licensing agreement with HMGene, a company focused on the genetics of obesity. Under the terms of the research agreement, HMGene will screen WellGen's proprietary bioactive compounds against HMGene's proprietary panel of genes involved in adipocyte development. Adipocyte development is the body's natural mechanism for making fat cells. The screening process will identify new, natural bioactive compounds that will be targeted to weight loss and the control of obesity. Any resulting products will be commercialized by WellGen.

PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/02-10-2005/0002991525&EDATE=)